El interés en corto de Natural Grocers da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Natural Grocers. Los datos de interés en corto se actualizan cada dos semanas.

Natural Grocers (NYSE:NGVC) Bolsa, Informe de interés en corto

Natural Grocers

Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.

Natural Grocers by Vitamin Cottage, Inc. Common Stock

Natural Grocers by Vitamin Cottage Inc

<p>Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Latham Group to report an <strong>earnings per share</strong> (EPS) of $-0.05.</p>
<p>Anticipation surrounds Latham Group's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.07, leading to a 36.81% increase in the share price the following trading session.</p>
<p>Here's a look at Latham Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.10</td>
<td>0.06</td>
<td>0.03</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.17</td>
<td>0.05</td>
<td>0.11</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>37.0%</td>
<td>-12.0%</td>
<td>41.0%</td>
<td>24.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464554_0.png" alt="eps graph" /></p>
<h3>Latham Group Share Price Analysis</h3>
<p>Shares of Latham Group were trading at $6.01 as of May 02. Over the last 52-week period, shares are up 100.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SWIM/earnings"><strong>To track all earnings releases for Latham Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

SWIM

A Look Ahead: Latham Group's Earnings Forecast

<p><strong>MRC Global</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that MRC Global will report an <strong>earnings per share</strong> (EPS) of $0.09. </p>
<p>Investors in MRC Global are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.16, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at MRC Global's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.08</td>
<td>0.19</td>
<td>0.26</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.08</td>
<td>0.22</td>
<td>0.31</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>15.0%</td>
<td>-5.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464545_0.png" alt="eps graph" /></p>
<h3>MRC Global Share Price Analysis</h3>
<p>Shares of MRC Global were trading at $12.09 as of May 02. Over the last 52-week period, shares are up 3.43%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on MRC Global</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MRC Global.</p>
<p>The consensus rating for MRC Global is Buy, derived from 4 analyst ratings. An average one-year price target of $15.25 implies a potential 26.14% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Custom Truck One Source, Distribution Solns Gr and Xometry, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Custom Truck One Source, with an average 1-year price target of $5.5, suggesting a potential 54.51% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Distribution Solns Gr, with an average 1-year price target of $44.0, suggesting a potential 263.94% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Xometry, with an average 1-year price target of $33.71, suggesting a potential 178.83% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Custom Truck One Source, Distribution Solns Gr and Xometry, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRC Global</td>
<td>Buy</td>
<td>-7.40%</td>
<td>$124M</td>
<td>-6.34%</td>
</tr>
<tr>
<td>Custom Truck One Source</td>
<td>Neutral</td>
<td>2.66%</td>
<td>$85.54M</td>
<td>-2.12%</td>
</tr>
<tr>
<td>Distribution Solns Gr</td>
<td>Outperform</td>
<td>14.89%</td>
<td>$163.98M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Xometry</td>
<td>Outperform</td>
<td>15.92%</td>
<td>$59.02M</td>
<td>-3.14%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MRC Global ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on Equity among its peers. Overall, MRC Global's performance is weaker compared to its peers in terms of financial metrics.</p>
<h3>All You Need to Know About MRC Global</h3>
<p>MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.</p>
<h3>MRC Global's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> MRC Global's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-7.4%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> MRC Global's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-5.9%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MRC Global's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-6.34%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> MRC Global's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.01%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> MRC Global's debt-to-equity ratio is below the industry average at <strong>1.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MRC/earnings"><strong>To track all earnings releases for MRC Global visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: MRC Global

<p>MFA Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect MFA Finl to report an <strong>earnings per share</strong> (EPS) of $0.32.</p>
<p>MFA Finl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 0.39% increase in the share price on the subsequent day.</p>
<p>Here's a look at MFA Finl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.40</td>
<td>0.41</td>
<td>0.38</td>
<td>0.39</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.39</td>
<td>0.37</td>
<td>0.44</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464536_0.png" alt="eps graph" /></p>
<h3>Performance of MFA Finl Shares</h3>
<p>Shares of MFA Finl were trading at $9.97 as of May 02. Over the last 52-week period, shares are down 7.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MFA/earnings"><strong>To track all earnings releases for MFA Finl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MFA Finl Earnings Preview

<p>Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Marcus to report an <strong>earnings per share</strong> (EPS) of $-0.31.</p>
<p>Marcus bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.08, which was followed by a 1.08% drop in the share price the next day.</p>
<p>Here's a look at Marcus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.11</td>
<td>0.46</td>
<td>0.03</td>
<td>-0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.03</td>
<td>0.78</td>
<td>-0.17</td>
<td>-0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>9.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464524_0.png" alt="eps graph" /></p>
<h3>Market Performance of Marcus's Stock</h3>
<p>Shares of Marcus were trading at $16.96 as of May 02. Over the last 52-week period, shares are up 45.91%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MCS/earnings"><strong>To track all earnings releases for Marcus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Marcus's Earnings Potential

<p>MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that MasterBrand will report an <strong>earnings per share</strong> (EPS) of $0.23.</p>
<p>Investors in MasterBrand are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $0.17 in the last quarter, leading to a 5.91% drop in the share price on the following day.</p>
<p>Here's a look at MasterBrand's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.38</td>
<td>0.34</td>
<td>0.41</td>
<td>0.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0.40</td>
<td>0.45</td>
<td>0.29</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-4.0%</td>
<td>-7.000000000000001%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464515_0.png" alt="eps graph" /></p>
<h3>Market Performance of MasterBrand's Stock</h3>
<p>Shares of MasterBrand were trading at $12.49 as of May 02. Over the last 52-week period, shares are down 29.35%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Views on MasterBrand</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MasterBrand.</p>
<p>Analysts have given MasterBrand a total of 2 ratings, with the consensus rating being Buy. The average one-year price target is $17.5, indicating a potential 40.11% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Janus Intl Gr, American Woodmark and Resideo Technologies, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Janus Intl Gr, with an average 1-year price target of $9.0, suggesting a potential 27.94% downside.</li>
<li>Analysts currently favor an Buy trajectory for American Woodmark, with an average 1-year price target of $75.0, suggesting a potential 500.48% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Resideo Technologies, with an average 1-year price target of $16.0, suggesting a potential 28.1% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Janus Intl Gr, American Woodmark and Resideo Technologies, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MasterBrand</td>
<td>Buy</td>
<td>-1.39%</td>
<td>$203.30M</td>
<td>1.08%</td>
</tr>
<tr>
<td>Janus Intl Gr</td>
<td>Outperform</td>
<td>-12.51%</td>
<td>$87.20M</td>
<td>0.06%</td>
</tr>
<tr>
<td>American Woodmark</td>
<td>Buy</td>
<td>-5.81%</td>
<td>$59.76M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Resideo Technologies</td>
<td>Neutral</td>
<td>20.88%</td>
<td>$530M</td>
<td>0.42%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MasterBrand is at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Delving into MasterBrand's Background</h3>
<p>MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.</p>
<h3>Understanding the Numbers: MasterBrand's Finances</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> MasterBrand's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-1.39%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.1%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MasterBrand's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.08%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> MasterBrand's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.48%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> MasterBrand's debt-to-equity ratio is below the industry average at <strong>0.84</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MBC/earnings"><strong>To track all earnings releases for MasterBrand visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

A Look at MasterBrand's Upcoming Earnings Report

<p>Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Supernus Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $0.39.</p>
<p>Supernus Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.25 in the last quarter, leading to a 2.74% drop in the share price on the following day.</p>
<p>Here's a look at Supernus Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.52</td>
<td>0.44</td>
<td>0.39</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.69</td>
<td>0.36</td>
<td>0</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>0.0%</td>
<td>14.000000000000002%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464507_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Supernus Pharmaceuticals were trading at $32.84 as of May 02. Over the last 52-week period, shares are up 4.62%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Supernus Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Supernus Pharmaceuticals.</p>
<p>With 2 analyst ratings, Supernus Pharmaceuticals has a consensus rating of Neutral. The average one-year price target is $36.0, indicating a potential 9.62% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Harmony Biosciences Hldgs and Tarsus Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Harmony Biosciences Hldgs, with an average 1-year price target of $54.5, suggesting a potential 65.96% upside.</li>
<li>Analysts currently favor an Buy trajectory for Tarsus Pharmaceuticals, with an average 1-year price target of $67.33, suggesting a potential 105.02% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Harmony Biosciences Hldgs and Tarsus Pharmaceuticals are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>5.99%</td>
<td>$148.06M</td>
<td>1.50%</td>
</tr>
<tr>
<td>Harmony Biosciences Hldgs</td>
<td>Buy</td>
<td>19.51%</td>
<td>$146.86M</td>
<td>7.88%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>Buy</td>
<td>183.68%</td>
<td>$73.12M</td>
<td>-8.86%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Supernus Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>About Supernus Pharmaceuticals</h3>
<p>Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.</p>
<h3>Supernus Pharmaceuticals's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Supernus Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>5.99%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.8%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Supernus Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.5%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Supernus Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Supernus Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/SUPN/earnings"><strong>To track all earnings releases for Supernus Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SUPN

Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview

Analyst Ratings

Trading Ideas

AMLP

CNBC Halftime Report Final Trades: Rockwell Automation, Alerian MLP ETF, Lockheed Martin Corporation, Stryker Corporation Common

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Super Micro Computer</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SMCI, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 26 uncommon options trades for Super Micro Computer.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 42%, bearish.</p>
<p>Out of all of the special options we uncovered, 15 are puts, for a total amount of $1,086,868, and 11 are calls, for a total amount of $428,198.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $3.0 to $90.0 for Super Micro Computer during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Super Micro Computer options trades today is 2399.92 with a total volume of 8,879.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Super Micro Computer's big money trades within a strike price range of $3.0 to $90.0 over the last 30 days.</p>
<h3>Super Micro Computer Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464505_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$57.35</td>
<td>$57.15</td>
<td>$57.27</td>
<td>$90.00</td>
<td>$274.8K</td>
<td>0</td>
<td align="right">48</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.85</td>
<td>$16.75</td>
<td>$16.75</td>
<td>$46.00</td>
<td>$194.3K</td>
<td>1.2K</td>
<td align="right">118</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$4.85</td>
<td>$4.75</td>
<td>$4.79</td>
<td>$28.00</td>
<td>$95.8K</td>
<td>28</td>
<td align="right">200</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$10.15</td>
<td>$10.05</td>
<td>$10.1</td>
<td>$33.00</td>
<td>$80.8K</td>
<td>785</td>
<td align="right">44</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$1.95</td>
<td>$1.92</td>
<td>$1.95</td>
<td>$20.00</td>
<td>$78.0K</td>
<td>298</td>
<td align="right">555</td>
</tr>
</tbody>
</table>
</p>
<h3>About Super Micro Computer</h3>
<p>Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, Big Data, high-performance computing, and the "Internet of Things" embedded markets. Its solutions include server, storage, blade, and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular, and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.</p>
<h3>Present Market Standing of Super Micro Computer</h3>
<ul>
<li>Currently trading with a volume of 19,655,512, the SMCI's price is down by -3.03%, now at $32.69. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>Expert Opinions on Super Micro Computer</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $40.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Mizuho has decided to maintain their Neutral rating on Super Micro Computer, which currently sits at a price target of $34.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Super Micro Computer, which currently sits at a price target of $55.<br />
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Neutral, setting a price target of $39.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Super Micro Computer with a target price of $39.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Super Micro Computer with a target price of $36. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

SMCI

Smart Money Is Betting Big In SMCI Options

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Merck &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Merck &amp; Co.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 22%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $518,376, and 2 are calls, for a total amount of $69,501.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $105.0 for Merck &amp; Co over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck &amp; Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck &amp; Co's significant trades, within a strike price range of $80.0 to $105.0, over the past month.</p>
<h3>Merck &amp; Co Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464500_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.81</td>
<td>$2.75</td>
<td>$2.76</td>
<td>$80.00</td>
<td>$276.0K</td>
<td>4.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.5</td>
<td>$12.45</td>
<td>$12.5</td>
<td>$95.00</td>
<td>$65.0K</td>
<td>224</td>
<td>53</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$24.5</td>
<td>$23.9</td>
<td>$24.15</td>
<td>$105.00</td>
<td>$50.9K</td>
<td>2</td>
<td>21</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.1</td>
<td>$21.75</td>
<td>$21.75</td>
<td>$105.00</td>
<td>$45.9K</td>
<td>1.6K</td>
<td>21</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$85.00</td>
<td>$36.4K</td>
<td>3.1K</td>
<td>149</td>
</tr>
</tbody>
</table>
</p>
<h3>About Merck &amp; Co</h3>
<p>Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.</p>
<p>Having examined the options trading patterns of Merck &amp; Co, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>With a volume of 3,732,912, the price of MRK is down -0.84% at $82.48. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for Merck &amp; Co</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $100.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $85.<br />
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $115. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Merck & Co Unusual Options Activity

<p><strong>Kimball Electronics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Kimball Electronics will report an <strong>earnings per share</strong> (EPS) of $0.19. </p>
<p>Kimball Electronics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.07, which was followed by a 0.73% increase in the share price the next day.</p>
<p>Here's a look at Kimball Electronics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.22</td>
<td>0.27</td>
<td>0.44</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.29</td>
<td>0.22</td>
<td>0.33</td>
<td>0.34</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>6.0%</td>
<td>-11.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464497_0.png" alt="eps graph" /></p>
<h3>Market Performance of Kimball Electronics's Stock</h3>
<p>Shares of Kimball Electronics were trading at $14.92 as of May 02. Over the last 52-week period, shares are down 33.08%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on Kimball Electronics</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Kimball Electronics.</p>
<p>A total of 1 analyst ratings have been received for Kimball Electronics, with the consensus rating being Buy. The average one-year price target stands at $21.0, suggesting a potential 40.75% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Methode Electronics, Benchmark Electronics and TTM Technologies, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Methode Electronics, with an average 1-year price target of $10.0, suggesting a potential 32.98% downside.</li>
<li>Analysts currently favor an Buy trajectory for Benchmark Electronics, with an average 1-year price target of $47.0, suggesting a potential 215.01% upside.</li>
<li>Analysts currently favor an Buy trajectory for TTM Technologies, with an average 1-year price target of $34.33, suggesting a potential 130.09% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Methode Electronics, Benchmark Electronics and TTM Technologies, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kimball Electronics</td>
<td>Buy</td>
<td>-15.16%</td>
<td>$23.43M</td>
<td>0.63%</td>
</tr>
<tr>
<td>Methode Electronics</td>
<td>Neutral</td>
<td>-7.55%</td>
<td>$41.30M</td>
<td>-2.00%</td>
</tr>
<tr>
<td>Benchmark Electronics</td>
<td>Buy</td>
<td>-6.49%</td>
<td>$63.18M</td>
<td>0.33%</td>
</tr>
<tr>
<td>TTM Technologies</td>
<td>Buy</td>
<td>-0.35%</td>
<td>$126.54M</td>
<td>2.04%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Kimball Electronics ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.</p>
<h3>Unveiling the Story Behind Kimball Electronics</h3>
<p>Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.</p>
<h3>Unraveling the Financial Story of Kimball Electronics</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Kimball Electronics's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-15.16%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Kimball Electronics's net margin is impressive, surpassing industry averages. With a net margin of <strong>0.96%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Kimball Electronics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.63%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.31%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.38</strong>.</p>
<p><a href="https://www.benzinga.com/quote/KE/earnings"><strong>To track all earnings releases for Kimball Electronics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: Kimball Electronics

<p>High-rolling investors have positioned themselves bullish on Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DOW often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Dow. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 62% bullish and 25% bearish. Among all the options we identified, there was one put, amounting to $29,680, and 7 calls, totaling $215,265.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.5 to $32.5 for Dow over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Dow options trades today is 4565.0 with a total volume of 2,013.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Dow's big money trades within a strike price range of $27.5 to $32.5 over the last 30 days.</p>
<h3>Dow Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464495_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.35</td>
<td>$27.50</td>
<td>$44.8K</td>
<td>4.3K</td>
<td align="right">105</td>
</tr>
<tr>
<td>DOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.3</td>
<td>$1.3</td>
<td>$1.3</td>
<td>$30.00</td>
<td>$32.5K</td>
<td>4.9K</td>
<td align="right">250</td>
</tr>
<tr>
<td>DOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$4.55</td>
<td>$3.75</td>
<td>$4.32</td>
<td>$30.00</td>
<td>$30.2K</td>
<td>557</td>
<td align="right">81</td>
</tr>
<tr>
<td>DOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.15</td>
<td>$2.12</td>
<td>$2.12</td>
<td>$30.00</td>
<td>$29.6K</td>
<td>11.8K</td>
<td align="right">160</td>
</tr>
<tr>
<td>DOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.45</td>
<td>$0.44</td>
<td>$0.45</td>
<td>$32.50</td>
<td>$28.4K</td>
<td>4.9K</td>
<td align="right">789</td>
</tr>
</tbody>
</table>
</p>
<h3>About Dow</h3>
<p>Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.</p>
<p>In light of the recent options history for Dow, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Dow</h3>
<ul>
<li>With a trading volume of 3,898,100, the price of DOW is down by -3.47%, reaching $29.36.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 80 days from now.</li>
</ul>
<h3>Expert Opinions on Dow</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Dow, which currently sits at a price target of $35.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Dow, which currently sits at a price target of $29.<br />
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Dow, maintaining a target price of $32.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Neutral rating on Dow, which currently sits at a price target of $37.<br />
&#x2A; Showing optimism, an analyst from Fermium Research upgrades its rating to Buy with a revised price target of $35. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Dow, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


This Is What Whales Are Betting On Dow

<p><strong>Ultragenyx Pharmaceutical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ultragenyx Pharmaceutical will report an <strong>earnings per share</strong> (EPS) of $-1.62. </p>
<p>Investors in Ultragenyx Pharmaceutical are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.12 in the last quarter, leading to a 2.37% drop in the share price on the following day.</p>
<p>Here's a look at Ultragenyx Pharmaceutical's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.27</td>
<td>-1.45</td>
<td>-1.72</td>
<td>-1.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.39</td>
<td>-1.40</td>
<td>-1.52</td>
<td>-2.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>14.000000000000002%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464483_0.png" alt="eps graph" /></p>
<h3>Performance of Ultragenyx Pharmaceutical Shares</h3>
<p>Shares of Ultragenyx Pharmaceutical were trading at $39.3 as of May 02. Over the last 52-week period, shares are down 6.76%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Insights on Ultragenyx Pharmaceutical</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Ultragenyx Pharmaceutical.</p>
<p>Analysts have provided Ultragenyx Pharmaceutical with 6 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $112.67, suggesting a potential 186.69% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of SpringWorks Therapeutics, Rhythm Pharmaceuticals and Catalyst Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for SpringWorks Therapeutics, with an average 1-year price target of $61.33, suggesting a potential 56.06% upside.</li>
<li>Analysts currently favor an Buy trajectory for Rhythm Pharmaceuticals, with an average 1-year price target of $73.29, suggesting a potential 86.49% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Catalyst Pharmaceuticals, with an average 1-year price target of $32.0, suggesting a potential 18.58% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for SpringWorks Therapeutics, Rhythm Pharmaceuticals and Catalyst Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultragenyx Pharmaceutical</td>
<td>Buy</td>
<td>29.42%</td>
<td>$147.98M</td>
<td>-44.30%</td>
</tr>
<tr>
<td>SpringWorks Therapeutics</td>
<td>Neutral</td>
<td>1029.96%</td>
<td>$55.99M</td>
<td>-15.25%</td>
</tr>
<tr>
<td>Rhythm Pharmaceuticals</td>
<td>Buy</td>
<td>72.61%</td>
<td>$38.04M</td>
<td>-286.92%</td>
</tr>
<tr>
<td>Catalyst Pharmaceuticals</td>
<td>Outperform</td>
<td>28.27%</td>
<td>$120.18M</td>
<td>8.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ultragenyx Pharmaceutical ranks at the bottom for Revenue Growth and Gross Profit, while it ranks at the top for Return on Equity. Overall, it is positioned in the middle compared to its peers.</p>
<h3>Get to Know Ultragenyx Pharmaceutical Better</h3>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Breaking Down Ultragenyx Pharmaceutical's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>29.42%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of <strong>-80.9%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-44.3%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-8.77%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ultragenyx Pharmaceutical's debt-to-equity ratio is below the industry average at <strong>0.16</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/RARE/earnings"><strong>To track all earnings releases for Ultragenyx Pharmaceutical visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RARE

Ultragenyx Pharmaceutical's Earnings: A Preview

<p>Stifel  analyst Stephen Gengaro   maintains ChampionX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHX#NASDAQ">CHX</a>) with a Buy and raises the price target from $39 to $40.</p>


News

Price Target

Stifel Maintains Buy on ChampionX, Raises Price Target to $40

<p><strong>Skyworks Solutions's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NYSE">SWKS</a>) short percent of float has risen 33.79% since its last report. The company recently reported that it has <strong>19.45 million shares sold short</strong>, which is 16.67% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.64 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Skyworks Solutions Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464432_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Skyworks Solutions has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Skyworks Solutions's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Skyworks Solutions's peer group average for short interest as a percentage of float is 5.11%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

SWKS

Is Skyworks Solutions Gaining or Losing Market Support?

<p><strong>Keysight Techs's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) short percent of float has risen 20.0% since its last report. The company recently reported that it has <strong>1.93 million shares sold short</strong>, which is 1.44% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.42 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Keysight Techs Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464426_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Keysight Techs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Keysight Techs's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Keysight Techs's peer group average for short interest as a percentage of float is 8.01%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


KEYS

How Is The Market Feeling About Keysight Techs?

<p>In the current market session, <strong>Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</strong> price is at $54.19, after a <strong>0.06%</strong> increase. However, over the past month, the stock fell by <strong>9.41%</strong>, and in the past year, by <strong>30.41%</strong>. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1746464421_0.png" alt="Past Year Chart" /></p>

<h3>Evaluating Hologic P/E in Comparison to Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>57.63</strong> in the Health Care Equipment &amp; Supplies industry, Hologic Inc. has a lower P/E ratio of <strong>22.76</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1746464421_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

HOLX

Price Over Earnings Overview: Hologic

<p><strong>Norfolk Southern's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) short percent of float has fallen 29.41% since its last report. The company recently reported that it has <strong>1.90 million shares sold short</strong>, which is 0.84% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.15 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Norfolk Southern Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746464421_0_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Norfolk Southern has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Norfolk Southern's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Norfolk Southern's peer group average for short interest as a percentage of float is 8.63%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Norfolk Southern's Recent Short Interest

<p>Shares of<strong> Cigna Group </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) rose in early Monday trading after the company announced <a href="https://www.benzinga.com/general/health-care/25/05/45165804/cigna-ceo-says-strong-q1-earnings-increased-outlook-reflect-strength-in-growth-platforms">upbeat first-quarter results on Friday</a>.</p>
<p>Here are some key analyst takeaways.</p>
<ul>
<li>Guggenheim Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62289c8626d7930001219176/jason-cassorla">analyst Jason Cassorla</a> maintained a Buy rating on the stock.</li>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/613f2550b4035700018da9d8/jessica-tassan">analyst Jessica Tassan</a> maintained an Overweight rating, while raising the price target from $348 to $374.</li>
</ul>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a></strong>.</p>
<p><strong>Guggenheim Securities</strong>: Cigna reported its first-quarter earnings at $6.74 per share, beating consensus of $6.35 per share. The company&#8217;s revenues were "well ahead of expectations, particularly within Evernorth," Cassorla said. Evernorth revenues grew by around 16% year-on-year to $53.68 billion, topping consensus of $50.3 billion, while Healthcare revenues rose 9% to $14.48 billion, surpassing consensus of $12.15 billion, he added.</p>
<p>Management raised the full-year earnings guidance by 10 cents per share. "Consensus comparisons are difficult due to timing related to the Medicare divestiture, but the lift in Healthcare pre-tax earnings guide against the delay in Medicare sale (runs at higher MLR) vs company expectations suggests favorable cost trend development for remaining businesses," he wrote.</p>
<p><strong>Piper Sandler</strong>: Cigna's earnings beat was led by Cigna Healthcare, Tassan said. Cigna Healthcare's MLR (medical loss ratio) came in at 82.2%, better than expectations of around 83%, despite headwinds from the timing of the Medicare Advantage sale to HCSC, which suggests that "trends in the continuing businesses were considerably better than forecast," she added.</p>
<p>The analyst stated that the raised guidance for Cigna Healthcare looks conservative based on the trends in the first quarter and utilization so far this year. </p>
<p>"Guidance called for 55.0% of Cigna Healthcare operating income in 1H25, with slightly more than half occurring in 1Q25," she added.</p>
<p><strong>CI Price Action:</strong> Shares of Cigna had risen by 0.13% to $334.33 at the time of publication on Monday.</p>
<p><strong>Read More:</strong> </p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus"><strong><u>Healthcare Stocks Decline After Trump Signs Executive Order On Price Transparency</u></strong></a></strong></li>
</ul>


Analyst Color

Earnings Beats

Reiteration

Cigna Packs Healthy Punch As Q1 Beat Sends Shares Higher, Analysts Raise Targets

<p>Stifel  analyst W. Andrew Carter   maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Hold and lowers the price target from $125 to $118.</p>


BLDR

Stifel Maintains Hold on Builders FirstSource, Lowers Price Target to $118

<p><strong>General Motors Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) announced an offering of senior <a href="https://www.benzinga.com/pressreleases/25/05/n45194081/general-motors-offers-senior-unsecured-notes">unsecured fixed-rate notes. </a></p>
<p><strong>What To Know: </strong>GM plans to use the proceeds to refinance part of $1.25 billion in 6.125% senior notes maturing in October 2025 and to help fund a $1.8 billion term loan to Ultium Cells, its joint venture with LG Energy Solution. </p>
<p>The loan will be used to fully prepay existing debt from the U.S. Department of Energy&#8217;s Advanced Technology Vehicles Manufacturing program. The move was presented as part of GM's broader debt management and investment strategy in its EV supply chain.</p>
<h3 class="wp-block-heading">Is General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) A Good Stock To Buy?</h3>
<p>When deciding whether to buy a stock, there are some key fundamentals investors may want to consider. One of these factors is revenue growth. Buying a stock is essentially a bet that the business will continue to grow and generate profits in the future.</p>
<p>General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has reported average annual revenue growth of 11.62% over the past 5 years. .</p>
<p>It's also important to pay attention to valuation when deciding whether to buy a stock. General Motors has a forward P/E ratio of 4.12. This means investors are paying $4.12 for each dollar of expected earnings in the future. The average forward of General Motors's peers is 27.72.</p>
<p>Other important metrics to look at include a company's profitability, balance sheet, performance relative to a benchmark index. For in-depth analysis tools and important financial data, check out <a href="https://pro.benzinga.com">Benzinga PRO</a>. </p>
<p><strong>Price Action: </strong>General Motors shares were up 0.67% at $45.608 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05114435/Screenshot-2025-05-05-at-11.44.13-1024x552.png" alt="" class="wp-image-901750" style="width:489px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05114435/Screenshot-2025-05-05-at-11.44.13-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05114435/Screenshot-2025-05-05-at-11.44.13-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05114435/Screenshot-2025-05-05-at-11.44.13-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05114435/Screenshot-2025-05-05-at-11.44.13.png 1511w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45192936/wall-street-veteran-investor-lowers-recession-risk-as-us-china-trade-war-cools">Wall Street Veteran Investor Lowers Recession Risk As US-China Trade War Cools</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>



Movers

What's Going On With General Motors Stock Today?

Press Releases

Natural Grocers® Invites Tyler, Texas Customers to Celebrate Store's 10th Anniversary March 28-30, 2025

Commodities

Natural Grocers® and Rodale Institute Celebrate Earth Month with Annual Ladybug Love Campaign, April 1-30, 2025

Natural Grocers® Expands Private-Label Beverage Line with 100% Organic Savory Spritzers

Natural Grocers® Expands Private Label Line with Non-GMO Peruvian Chips

Celebrate a good4u℠ Easter with Natural Grocers®

Natural Grocers® Honors Earth Day with Special Deals, Freebies and Sweepstakes

Natural Grocers® Celebrates National North Dakota Day with Special Gifts and Savings, April 19-21, 2025

Natural Grocers® Honors Arbor Day in Nebraska, with a Freebie and $5 Off, April 25-27, 2025

Natural Grocers by Vitamin Cottage, Inc. Announces Second Quarter Fiscal Year 2025 Earnings Conference Call and Webcast

Natural Grocers® Celebrates Montana Day with Free Tote Bags, $5 Off for {N}power® Members

NGVC

Albertsons Companies, Inc. Class A Common Stock

Albertsons Companies

Maplebear

Caseys General Stores, Inc. - Common Stock

Casey's General Stores

Chanson International Holding - Class A Ordinary Shares

Chanson International

Dingdong (Cayman) Limited American Depositary Shares (each two representing three Ordinary Shares)

Comments

Natural Grocers

Interés en corto

Natural Grocers (NYSE:NGVC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL